A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
OBJECTIVE
To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer.


METHODS
Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m²) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy)± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS).


RESULTS
Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age=58 years (range: 21-81 years). 78% (32/41)=endometrioid histology. Stages=10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent=1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%).


CONCLUSIONS
"Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.
Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA. gelle005@umn.edu
Melissa A
MA
Geller
Joseph J
JJ
Ivy
Rahel
R
Ghebre
Levi S
LS
Downs
Patricia L
PL
Judson
Linda F
LF
Carson
Amy L
AL
Jonson
Kathryn
K
Dusenbery
Rachel Isaksson
RI
Vogel
Matthew P
MP
Boente
Peter A
PA
Argenta
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001918:Brachytherapy / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018269:Carcinoma, Endometrioid / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000009:adverse effects; D018572:Disease-Free Survival; D000077143:Docetaxel; D019583:Dose Fractionation, Radiation; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000532:radiotherapy*; D009367:Neoplasm Staging; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin
Gynecol Oncol. 2009 Jul;114(1):94-8
19406459
Gynecol Oncol. 2004 May;93(2):345-52
15099944
Gynecol Oncol. 2006 Nov;103(2):451-7
16677690
Gynecol Oncol. 2008 Jan;108(1):201-6
17997145
Gynecol Oncol. 2010 Jul;118(1):19-23
20381136
Gynecol Oncol. 2009 Oct;115(1):18-25
19632708
Gynecol Oncol. 2010 Apr;117(1):32-6
20060158
Gynecol Oncol. 2005 Jun;97(3):755-63
15913742
Gynecol Oncol. 2006 Feb;100(2):349-54
16213007
Eur J Gynaecol Oncol. 2004;25(5):591-3
15493172
Am J Obstet Gynecol. 2005 May;192(5):1365-7
15902110
Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82
9346228
Gynecol Oncol. 2009 Mar;112(3):543-52
19108877
J Cancer Res Clin Oncol. 2005 Sep;131(9):581-4
15959825
Gynecol Oncol. 2008 Oct;111(1):22-6
18675446
Br J Cancer. 2005 Oct 31;93(9):999-1004
16234823
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53
11483323
J Clin Oncol. 2006 Jan 1;24(1):36-44
16330675
J Clin Oncol. 2004 Oct 1;22(19):3902-8
15459211
Gynecol Oncol. 2006 Oct;103(1):155-9
16545437
Gynecol Oncol. 2007 Nov;107(2):285-91
17688923
J Clin Oncol. 2001 Oct 15;19(20):4048-53
11600606
Gynecol Oncol. 1989 Apr;33(1):68-70
2703169
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
20610543
Br J Cancer. 1997;75(12):1836-41
9192991
Gynecol Oncol. 2007 Jan;104(1):86-90
16996111
Cancer. 1993 Jun 1;71(11):3697-702
8490920
Br J Cancer. 2003 Dec 1;89(11):2023-6
14647132
Gan To Kagaku Ryoho. 2000 Feb;27(2):257-62
10700897
J Clin Oncol. 2004 Jun 1;22(11):2159-66
15169803